1. Global Immune Checkpoint Inhibitor Market Overview
1.1 Current Market Scenario
1.2 Future Market Opportunity
2. CTLA4 Protein Inhibitors Biomarkers and Clinical Trials Insight By Company, Indication and Phase
2.1 Research
2.2 Preclinical
2.3 Phase-I
2.4 Phase-I/II
2.5 Phase-II
2.6 Phase-III
2.7 Preregistration
4. Global LAG3 Inhibitors Clinical Pipeline By Company, Indication and Phase
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-I/II
4.5 Phase-II
4.6 Phase-II/III
4.7 Phase-III
4.8 Preregistration
5. PD-1/PD-L1 Inhibitors Biomarkers and Clinical Trials Insight By Company, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase-I
5.4 Phase-I/II
5.5 Phase-II
5.6 Phase-II/III
5.7 Phase-III
5.8 Preregistration
5.9 Registered
7. TIGIT Protein Inhibitors Biomarkers and Clinical Trials Insight By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
8. PD-1/PD-L1 Immune Checkpoint Inhibitor - Availability, Patent, Price and Dosage Analysis
8.1 Pembrolizumab (Keytruda )
8.2 Nivolumab (Opdivo)
8.3 Durvalumab (Imfinzi)
8.4 Avelumab (Bavencio)
8.5 Atezolizumab (Tecentriq)
8.6 Cemiplimab (Libtayo)
8.7 Dostarlimab (Jemperli)
8.8 Toripalimab (Tuoyi)
8.9 Sintilimab (Tyvyt)
8.10 Camrelizumab (AiRuiKa)
8.11 Tislelizumab (Baize’an)
8.12 Envafolimab (Enweida)
8.13 Sugemalimab (Cejemly)
8.14 Zimberelimab
8.15 Penpulimab
9. CTLA-4 Immune Checkpoint Inhibitor - Availability, Patent, Price and Dosage Analysis
9.1 Ipilimumab (Yervoy)
10. Global Immune Checkpoint Inhibitors Sales Insights 2028
10.1 Keytruda
10.2 Yervoy
10.3 Opdivo
10.4 Imfinzi
10.5 Tecentriq
10.6 Libtayo
10.7 Jemperli
10.8 Bavencio
10.9 Tyvyt
11. Competitive Landscape
11.1 Amgen
11.2 AstraZeneca
11.3 Bristol Myers Squibb
11.4 F-Star Therapeutics
11.5 GlaxoSmithKline
11.6 Immutep
11.7 Innovent
11.8 Macrogenics
11.9 Merck
11.10 Nanobiotix
11.11 Novartis
11.12 Ono Pharmaceutical
11.13 Pfizer
11.14 Roche
11.15 Shanghai Junshi Biosciences
List of Figures
Figure 1-1: Global – Immune Checkpoint Inhibitors Market Size (US$ Billion), 2020 and 2021
Figure 1-2: Global – Immune Checkpoint Inhibitors Market by Region (US$ Billion), 2021
Figure 1-3: Global – Immune Checkpoint Inhibitors Market by Region (%), 2021
Figure 1-4: Global – Immune Checkpoint Inhibitors Market by Product (US$ Billion), 2021
Figure 1-5: Global – Immune Checkpoint Inhibitors Market by Product (%), 2021
Figure 1-6: Global – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2022 - 2028
Figure 1-7: US – Immune Checkpoint Inhibitors Market Opportunity (US$ Billion), 2022 - 2028
Figure 8-1: Keytruda – Approval Year by Region
Figure 8-2: Keytruda – FDA Approval Year by Indication
Figure 8-3: Keytruda – Patent Expiration Year by Region
Figure 8-4: US - Price for 4ml, 8ml Supply and Price Per ml of Keytruda Intravenous Injection (US$), February’2022
Figure 8-5: UK - Price for 4ml and Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), February’2022
Figure 8-6: Keytruda – Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks), February’2022
Figure 8-7: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), February’2022
Figure 8-8: Opdivo – Approval Year by Region
Figure 8-9: Opdivo – FDA Approval by Indication
Figure 8-10: Opdivo - Patent Expiration Year by Region
Figure 8-11: US - Price for 4ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), February’2022
Figure 8-12: US - Price for 10 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), February’2022
Figure 8-13: US - Price for 12 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), February’2022
Figure 8-14: US - Price for 24 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), February’2022
Figure 8-15: UK - Price for 4 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), February’2022
Figure 8-16: UK - Price for 10ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), February’2022
Figure 8-17: UK - Price for 24ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), February’2022
Figure 8-18: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), February’2022
Figure 8-19: Imfinzi – FDA Approval Year by Indication
Figure 8-20: Imfinzi – Approval Year by Region
Figure 8-21: Imfinzi – FDA Approval and Patent Expiration Year
Figure 8-22: US– Price for a Supply of 2.4ml and Price Per ml of Imfinzi Solution for Injection (US$), February’2022
Figure 8-23: US – Price for a Supply of 10 ml and Price Per ml of Imfinzi Solution for Injection (US$), February’2022
Figure 8-24: UK– Price for a Supply of 2.4ml and Price Per ml of Imfinzi Solution for Injection (GBP/US$), February’2022
Figure 8-25: UK– Price for a Supply of 10ml and Price Per ml of Imfinzi Solution for Injection (GBP/US$), February’2022
Figure 8-26: Imfinzi - Average Cost of Single Treatment Cycle and Full Treatment of NSCLC (US$), February’2022
Figure 8-27: Bavencio – FDA Approval Year by Indication
Figure 8-28: Bavencio - Price for 10ml Supply and Price Per ml of 20mg/ml Intravenous Injection (US$), February’2022
Figure 8-29: UK– Price for a Supply of 10ml and Price Per ml of Bavencio Solution for Injection (GBP/US$), February’2022
Figure 8-30: Bavencio - Average Cost of Single Treatment Cycle and Annual Treatment (US$), February’2022
Figure 8-31: Tecentriq – Approval Year by Region
Figure 8-32: Tecentriq – FDA Approval Year by Indication
Figure 8-33: US- Price for 14ml Supply and Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), February’2022
Figure 8-34: US - Price for 20ml Supply and Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), February’2022
Figure 8-35: UK– Price for a Supply of 20ml and Price Per ml of Tecentriq Solution for Injection (GBP/US$), February’2022
Figure 8-36: UK– Price for a Supply of 14ml and Price Per ml of Tecentriq Solution for Injection (GBP/US$), February’2022
Figure 8-37: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), February’2022
Figure 8-38: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), February’2022
Figure 8-39: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), February’2022
Figure 8-40: Libtayo – Approval Year by Region
Figure 8-41: Libtayo – FDA Approval Year by Indication
Figure 8-42: US– Price for a Supply of 7ml and Price Per ml of Libtayo Solution for Injection (US$), February’2022
Figure 8-43: UK– Price for a Supply of 7ml and Price Per ml of Libtayo Solution for Injection (GBP/US$), February’2022
Figure 8-44: Libtayo – Cost of Single Treatment Cycle and Annual Treatment Cost (US$), February’2022
Figure 8-45: US– Price for a Supply of 10ml and Price Per ml of Jemperli Solution for Injection (US$), February’2022
Figure 8-46: UK– Price for a Supply of 10ml and Price Per ml of Jemperli Solution for Injection (GBP/US$), February’2022
Figure 8-47: Jemperli - Average Dose of Initial 4 Cycles and Subsequent Cycles (mg)
Figure 8-48: Jemperli - Average Cost of Initial 4 Cycles and Subsequent Cycles (US$), February’2022
Figure 8-49: Tuoyi – NMPA Approval by Indication
Figure 8-50: China– Price for a Supply of 2ml and Price Per ml of Tuoyi Solution for Injection (Yuan/US$), February’2022
Figure 8-51: China– Price for a Supply of 2.5ml and Price Per ml of Tuoyi Solution for Injection (Yuan/US$), February’2022
Figure 8-52: China– Price for a Supply of 6ml and Price Per ml of Tuoyi Solution for Injection (Yuan/US$), February’2022
Figure 8-53: Tyvyt – NMPA Approval by Indication
Figure 8-54: China– Price for Vial of AiRuiKa (Yuan/US$), February’2022
Figure 8-55: Tislelizumab – NMPA Approval by Indication
Figure 8-56: China– Price for Vial of Penpulimab (Yuan/US$), February’2022
Figure 9-1: Yervoy – Approval Year by Region
Figure 9-2: Yervoy – FDA Approval Year by Indication
Figure 9-3: Yervoy – US and Europe Exclusivity Expiration Year
Figure 9-4: US - Price for 10ml Supply and Price Per ml of Yervoy 5mg/ml Intravenous Injection (US$), February’2022
Figure 9-5: US – Price for 40ml Supply and Price Per ml 5mg/ml Yervoy Intravenous Injection (US$), February’2022
Figure 9-6: UK - Price for 10ml and Price Per ml of Yervoy 50mg Intravenous Injection (GBP/US$), February’2022
Figure 9-7: UK - Price for 40ml and Price Per ml of Yervoy 200mg Intravenous Injection (GBP/US$), February’2022
Figure 9-8: Yervoy – Duration of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (Weeks), February’2022
Figure 9-9: Yervoy – Average Cost of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (US$), February’2022
Figure 9-10: Yervoy – Average Cost of Single Treatment Cycle, Initial Year and Remaining Years for Management of Metastatic Melanoma (US$), February’2022
Figure 10-1: Global - Keytruda Annual Sales Value (US$ Billion), 2018 - 2021
Figure 10-2: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
Figure 10-3: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
Figure 10-4: Global - Yervoy Annual Sales Value (US$ Million), 2018 - 2021
Figure 10-5: US - Yervoy Annual Sales Value (US$ Million), 2018 - 2021
Figure 10-6: Yervoy - Annual Sales Value by Region (US$ Million), 2021
Figure 10-7: Yervoy - Annual Sales Value by Region (US$ Million), 2021
Figure 10-8: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 10-9: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 10-10: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 10-11: US - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 10-12: Global - Opdivo Annual Sales Value (US$ Million), 2021
Figure 10-13: US - Opdivo Annual Sales Value (US$ Million), 2021
Figure 10-14: Global - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 10-15: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 10-16: Global - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 10-17: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 10-18: Global - Imfinzi Annual Sales Value (US$ Million), 2019 - 2021
Figure 10-19: US - Imfinzi Annual Sales Value (US$ Million), 2019 - 2021
Figure 10-20: Europe - Imfinzi Annual Sales Value (US$ Million), 2019 - 2021
Figure 10-21: Imfinzi - Annual Sales Value by Region (US$ Million), 2021
Figure 10-22: Imfinzi - Annual Sales Value by Region (%), 2021
Figure 10-23: Global - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 10-24: US - Imfinzi Quarterly Sales Value US$ Million), 2021
Figure 10-25: Global - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 10-26: US - Imfinzi Quarterly Sales Value US$ Million), 2020
Figure 10-27: Global - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 10-28: US - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 10-29: Europe - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 10-30: Japan - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 10-31: ROW - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 10-32: Tecentriq - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 10-33: Tecentriq - Annual Sales Value by Region (%), 2021
Figure 10-34: Global - Tecentriq Quarterly Sales Value (US$ Billion), 2021
Figure 10-35: US - Tecentriq Quarterly Sales Value (US$ Billion), 2021
Figure 10-36: US - Tecentriq Quarterly Sales Value (US$ Million), 2020
Figure 10-37: Global - Libtayo Annual Sales Value (US$ Million), 2018 - 2021
Figure 10-38: US - Libtayo Annual Sales Value (US$ Million), 2018 - 2021
Figure 10-39: Libtayo - Annual Sales Value by Region (US$ Million), 2021
Figure 10-40: Libtayo - Annual Sales Value by Region (%), 2021
Figure 10-41: Global - Libtayo Quarterly Sales Value (US$ Million), 2021
Figure 10-42: US - Libtayo Quarterly Sales Value (US$ Million), 2021
Figure 10-43: Global - Libtayo Quarterly Sales Value (US$ Million), 2020
Figure 10-44: US - Libtayo Quarterly Sales Value (US$ Million), 2020
Figure 10-45: Global - Jemperli Annual Sales Value by Region (US$/GBP Million), 2021
Figure 10-46: Global - Jemperli Annual Sales Value by Region (%), 2021
Figure 10-47: US - Jemperli Quarter Sales Value (US$/GBP Million), Q3 and Q4’2021
Figure 10-48: Global - Bavencio Annual Sales Value (US$ Million), 2020 and 2021
Figure 10-49: US - Bavencio Annual Sales Value (US$ Million), 2020 and 2021
Figure 10-50: Europe - Bavencio Annual Sales Value (US$ Million), 2020 and 2021
Figure 10-51: Bavencio - Annual Sales Value by Region (US$ Million), 2021
Figure 10-52: Bavencio - Annual Sales Value by Region (%), 2021
Figure 10-53: Global - Tyvyt Annual Sales Value (US$ Million), 2019 - 2021
Figure 10-54: Global - Tyvyt Quarterly Sales Value (US$ Million), 2021
Figure 10-55: Global - Tyvyt Quarterly Sales Value (US$ Million), 2020
List of Tables
There Are More Than 500 Tables Representing Comprehensive Information On Biomarkers By Immune Checkpoint Inhibitors Clinical Trials And Indication